Federal Circuit Affirms Invalidity Of Cancer Treatment Patents For Lack Of Enablement
The U.S. Federal Circuit affirmed a Delaware ruling that invalidated Wyeth LLC’s cancer treatment patents against AstraZeneca, removing an infringement damages award of about $107.5 million. The court found the patents lacked enablement under 35 U.S.C. §112(a), citing insufficient guidance to translate in vitro data into therapeutically effective human daily dosing, under the Amgen framework.
How this was made
The 30-second read
Why it matters
The Federal Circuit affirmed the invalidity determination, applying the Supreme Court’s enablement framework from Amgen v. Sanofi and emphasizing that the specification must teach how to practice the full claimed scope without undue experimentation.
Market read
This is a precedential patent enablement win for AstraZeneca that removes a large infringement damages award tied to the asserted claims.
What to watch
The brief does not quantify whether AstraZeneca faces other active claims or whether Tagrisso has separate, still-valid patents that preserve exclusivity or licensing leverage.
Background
Wyeth sued AstraZeneca in 2021 over alleged induced infringement of two patents covering daily dosing methods for EGFR inhibitor treatment in resistant NSCLC; a jury awarded about $107.5M before the district court invalidated the claims for lack of enablement.
Ticker impact
Federal Circuit affirmed invalidity of Wyeth’s patents tied to AstraZeneca’s Tagrisso (osimertinib), erasing a roughly $107.5M infringement award.
Near-term: limited single-name impact unless investors were pricing ongoing infringement risk; medium-term: modest relief for legal-risk premium.
The article frames a precedential enablement invalidity decision that eliminates the infringement damages, but it provides no new Tagrisso commercial or regulatory facts.
Market effects
Reinforces post-Amgen enablement scrutiny for method-of-treatment patents, potentially pressuring other pharma patent portfolios with broad claims based on in vitro data.
US-focused appellate precedent may influence litigation strategy for US patent enforcement across global pharma.
Could affect cross-border patent enforcement and licensing negotiations for EGFR inhibitor treatment regimens.
Counterpoint
If investors already expected enablement challenges to succeed, the decision may be largely priced in, limiting incremental price reaction.
Key entities
- plaintiffWyeth LLC
Alleged induced infringement of two asserted patents tied to EGFR inhibitor treatment methods.
- defendantAstraZeneca Pharmaceuticals LP
Marketed Tagrisso (osimertinib), accused of inducing infringement; benefited from invalidity affirmation.
- productTagrisso (osimertinib)
AstraZeneca’s EGFR inhibitor referenced as the accused marketed therapy.
- courtU.S. Court of Appeals for the Federal Circuit
Affirmed the district court’s lack-of-enablement invalidity ruling.
